OPEN LETTER

COVID-19 vaccine delivery: an opportunity to set up systems for the future [version 1; peer review: 2 approved with reservations]

Rebecca Weintraub1,2, Stanley Plotkin3, Margaret Liu4, Jerome Kim5, Natalie Garcon6, David Bell7, Dan Storisteanu8,9, Toby Norman9, Eliah Aronoff-Spencer10

1Ariadne Labs, Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital Boston, Boston, MA, 02215, USA
2Harvard Medical School, Cambridge, MA, USA
3University of Pennsylvania School of Medicine, Philadelphia, PA, USA
4ProtherImmune, Lafayette, CA, USA
5International Vaccine Institute, Seoul, Seoul, South Korea
6Bioaster Technology Research Institute, Lyon, France
7Independent Researcher, Seattle, Washington, USA
8University of Cambridge, Cambridge, UK
9Simprints, Cambridge, UK
10School of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, Ca, 92093, USA

First published: 18 Dec 2020, 4:182
https://doi.org/10.12688/gatesopenres.13210.1
Latest published: 14 Apr 2021, 4:182
https://doi.org/10.12688/gatesopenres.13210.2

Abstract
The race to develop safe and effective SARS-COV-2 vaccines has moved with unprecedented speed. There are now multiple promising candidates seeking emergency use authorization from the United States Food and Drug Administration and a host of candidates positioned for approval worldwide. Attention has now turned to allocation, distribution and verification of these vaccines, yet this focus exposes that the underlying infrastructure for global delivery and monitoring is threadbare and unevenly distributed. This presents both a barrier and an opportunity to deploy sustainable infrastructure. Major global stakeholders must convene quickly, collaborate, and collectively invest in global standards, legal models, common vocabularies and interoperable biometric-supported digital health technologies. As the COVID-19 vaccine effort scales, governments, private sector and NGOs have the chance to place lasting resources needed for equitable and effective delivery that can pay dividends into the future.
Keywords
vaccine deliver, biometrics, identity, immunizations, health systems strengthening, health service deliver, COVID-19, COVID-19 vaccine, SARS-COV-2 vaccine, SARS-COV-2

This article is included in the Coronavirus (COVID-19) collection.

Corresponding authors: Rebecca Weintraub (rweintraub@bwh.harvard.edu), Eliah Aronoff-Spencer (earonoffspencer@health.ucsd.edu)

Author roles: Weintraub R: Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; Plotkin S: Writing – Original Draft Preparation, Writing – Review & Editing; Liu M: Writing – Original Draft Preparation, Writing – Review & Editing; Kim J: Writing – Original Draft Preparation, Writing – Review & Editing; Garcon N: Writing – Original Draft Preparation, Writing – Review & Editing; Bell D: Writing – Original Draft Preparation, Writing – Review & Editing; Storisteanu D: Writing – Original Draft Preparation, Writing – Review & Editing; Norman T: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; Aronoff-Spencer E: Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: Toby Norman is CEO of Simprints, a UK based non-profit developing biometric technology. Dan Stori is the Director of Research at Simprints. No other author has any financial conflict of interest to declare.

Grant information: This work was supported by the Bill and Melinda Gates Foundation [OPP1159073]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Weintraub R et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Weintraub R, Plotkin S, Liu M et al. COVID-19 vaccine delivery: an opportunity to set up systems for the future [version 1; peer review: 2 approved with reservations] Gates Open Research 2020, 4:182 https://doi.org/10.12688/gatesopenres.13210.1

First published: 18 Dec 2020, 4:182 https://doi.org/10.12688/gatesopenres.13210.1
As we get closer and closer to an effective SARS-CoV-2 vaccine, policymakers, academics, and scientists around the globe are turning their attention to yet another fundamental challenge - how will governments monitor and verify vaccine delivery.

An effective vaccination program will falter if we don’t invest in the information infrastructure for vaccine delivery in developed and low and middle-income countries alike. There is little evidence that we are ready for this. Glaring data gaps exist at numerous levels of global identity and health information exchange. Data on routine immunization already faces deep challenges. Studies show, for example, that despite WHO coverage estimates near 99%, up to 54% of children do not actually receive timely measles vaccinations in Bangladesh. Widespread gaps in data quality, reporting, and patient identification in routine vaccine delivery disrupt services and presage COVID-19 vaccine delivery challenges in the near future.

The supply of the first generation COVID-19 vaccines will be scarce, and each course must reach the intended recipient. Corruption, leakage, spoilage and even accidental duplications are deadly. Most current COVID-19 vaccine candidates require a two-dose course; patients will need to be reliably identified to ensure appropriate spacing of doses. Further, long-term efficacy remains to be seen and will require accurate, longitudinal patient data. Tracking patient data over time and across service delivery points requires patient identification systems. Patient identification systems will be the hardest to achieve in the places they are needed most. Many low-income countries lack a foundational government-issued ID. About one billion people lack any official civil registration.

We do have some options to face this disturbing scenario and one involves biometric digital identity.

The foundational ID challenge will not be solved in time for the release of a COVID-19 vaccine. However, organizations like Gavi have identified biometric digital identity as a potential lever to bridge the identity gap and ensure accurate data. Done properly, these systems can be privacy preserving, interoperable, portable, secure, and capable of serving both adult and children’s needs. Interoperability standards will ensure these systems can plug into foundational ID programs as coverage expands over the next decade, and privacy-first architecture design is already underway in several projects.

Biometric immunization registries can deliver both COVID-19 vaccines and serve routine immunizations which are becoming less routine as the pandemics secondary effects become more prominent. We should be developing these architectures now - months before the ramp up of vaccine delivery begins and before further lapses in basic primary health lead to explosions of other vaccine preventable illnesses. Missing this chance could waste significant time, effort, and the chance to build forward-looking infrastructure that serves basic healthcare long into the future.

During the latest Ebola epidemic, a rush of technologies were hastily assembled to track and combat the disease, leading to massive duplication of efforts and half-built tools that were abandoned after the crisis.

We know what is coming. In the next quarter all attention will be on the allocation, distribution and verification of COVID-19 vaccine delivery. Routine immunizations will be disrupted. Investing in the infrastructure that can support COVID-19 vaccine delivery and routine immunizations, for everyone young and old, can ensure that we are taking advantage of this opportunity amidst the challenges and putting countries on track to fight not only this pandemic, but pressing public health needs for years to come.

Major global stakeholders must convene, collaborate, and collectively invest in global standards, legal infrastructure, common vocabularies and interoperable biometrically-supported digital health technologies. This will pay dividends long after the world’s attention has shifted. If done transparently, this infrastructure can enhance trust in vaccines, something critical to clinical trial enrolment and widespread public adoption.

We have a narrow opportunity to set the stage for fair and sustainable infrastructure across the globe. If done well, we can ensure the promise of the COVID-19 vaccine portfolio leads to future widespread vaccination - and protection - for global populations.

Data availability
No data are associated with this article.

References


Open Peer Review

Current Peer Review Status: ❑ ❑

Version 1

Reviewer Report 20 January 2021

https://doi.org/10.21956/gatesopenres.14427.r30148

© 2021 Gelb A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alan Gelb
Center for Global Development, Washington, DC, USA

The paper addresses an important issue: the pace of Covid-19 vaccine deployment is outstripping the data systems needed to manage and document it. There is a risk of ending up with multiple, disconnected systems, many of low quality, especially in countries that do not have a strong and widely held national ID credential. Accurate identification of those receiving vaccines (and also of those administering them) is an essential part of such systems.

My first suggestion is to: distinguish more clearly between the stages -- national vaccine supply chain management, national vaccination rollout management, and international certification. The priorities for ID are different across these stages;

A second suggestion is to be clear on the role of inter-operability and standards for each stage. Within countries, it is important to head off the growth of multiple, non-interoperable, systems; therefore some national standards will be needed, including for identification. A successful "global vaccination passport" will require the capability for mutual recognition, but will almost surely have to be built on the basis of differing national systems, just as the current passport system is built on very different registration and ID systems.

The third suggestion is to flag some major tradeoffs that will need to be negotiated. One concerns the time and access to technology needed to enroll people for a vaccination program in a way that would be interoperable with a national ID. Mass vaccination needs to be fast and inclusive. It can be a driver for increasing registration, but only if this is managed well and if there is trust in the system. Another is the potential tradeoff between digital vaccination systems and privacy. Technical approaches are being proposed to give people control over their data (see the article in The Guardian, January 15) but the big concern is the credibility of many governments. It may be that privacy and surveillance concerns slow the emergence of an international consensus on national registration systems. Nevertheless, countries will need to move forward in developing effective national vaccination management programs.

Is the rationale for the Open Letter provided in sufficient detail?
Yes

Does the article adequately reference differing views and opinions?
Partly

Are all factual statements correct, and are statements and arguments made adequately supported by citations?
Yes

Is the Open Letter written in accessible language?
Yes

Where applicable, are recommendations and next steps explained clearly for others to follow?
Partly

Competing Interests: Some of the contributing authors are with Simprints. I am on the Advisory Board of that company. I do not believe that this constitutes a conflict of interest but am flagging it for transparency.

Reviewer Expertise: ID systems and economic development.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 15 January 2021

https://doi.org/10.21956/gatesopenres.14427.r30150

© 2021 Nelson K. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kristin Nelson
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA

This is a timely article that describes a key barrier to successful SARS-CoV-2 vaccine rollout globally – the lack of effective systems to record vaccinations. The authors propose the use of biometric digital identifiers to identify vaccinated individuals and monitor progress of vaccine administration. The rationale is clearly laid out, but several comments to improve the letter are below.

Major comments:
The authors recommend the use of biometric immunization registries, but do not clearly explain what they are and how they would work. A description of this system for the uninitiated reader is
necessary.

Can the authors comment on the feasibility of implementing biometric ID programs on national level (would they be implemented on a national level?) with only several months' lead time? Are projects to implement these systems already underway that could be accelerated? The authors make the case that there is a problem that needs to be solved, but not that these tools are well-positioned to solve it in the short time required.

It may be relevant to include how these concerns are magnified given that a vaccine for COVID-19 will likely be targeted towards adults and many immunization programs in LMIC are set up primarily to administer childhood vaccinations. There is a significant disconnect here between the current structure and function of national immunization programs and what they would asked to do to widely administer a COVID-19 vaccine.

Minor comments:
The abstract and first paragraph should be updated to reflect the recent approval and rollout of several vaccines in high-income countries.

Are there alternatives to these systems for the ID challenge? If so, please briefly mention and explain why biometric identifiers are a better solution.

Is the rationale for the Open Letter provided in sufficient detail?
Yes

Does the article adequately reference differing views and opinions?
No

Are all factual statements correct, and are statements and arguments made adequately supported by citations?
Yes

Is the Open Letter written in accessible language?
Yes

Where applicable, are recommendations and next steps explained clearly for others to follow?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** infectious disease epidemiology, respiratory infections, vaccines

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.